Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Top Cited Papers
Open Access
- 7 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 29 (8), 2104-2114
- https://doi.org/10.1007/s11095-012-0739-z
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trialThe Lancet, 2011
- Insulin Degludec in Type 1 DiabetesDiabetes Care, 2011
- A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2011
- Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product DevelopmentPharmaceutical Research, 2010
- Immunogenicity of protein therapeutics: The key causes, consequences and challengesSelf/Nonself, 2010
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulinBiochemistry, 1989
- The Specific Refractive Increment of Some Purified ProteinsJournal of the American Chemical Society, 1948